AXSM:NSD-Axsome Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 41.12

Change

+1.02 (+2.54)%

Market Cap

USD 1.51B

Volume

1.23M

Avg Analyst Target

USD 72.67 (+80.85%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+10.63 (+3.28%)

USD130.87B 38.30 29.43
BNTX BioNTech SE

+13.41 (+5.41%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

-9.76 (-1.76%)

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

-0.97 (-0.53%)

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+2.38 (+0.66%)

USD33.45B N/A N/A
SGEN Seagen Inc

-0.76 (-0.44%)

USD31.43B 53.89 40.74
GMAB Genmab A/S

+0.07 (+0.16%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

-4.66 (-2.23%)

USD24.79B N/A N/A
RPRX Royalty Pharma plc

-1.37 (-3.57%)

USD23.31B 31.09 11.82

ETFs Containing AXSM

Symbol Name Weight Mer Price(Change) Market Cap
DWAQ Invesco DWA NASDAQ Moment.. 0.00 % 0.60 %

N/A

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.53% 16% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.53% 16% F 8% F
Trailing 12 Months  
Capital Gain -42.93% 22% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.93% 22% F 8% F
Trailing 5 Years  
Capital Gain 478.34% 90% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 478.34% 90% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 266.93% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.93% 95% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 572.53% 5% F 3% F
Risk Adjusted Return 46.62% 73% C 64% D
Market Capitalization 1.51B 80% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 17.21 7% F 7% F
Price / Cash Flow Ratio -19.26 76% C 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -100.70% 25% F 18% F
Return on Invested Capital -54.93% 45% F 15% F
Return on Assets -40.21% 20% F 7% F
Debt to Equity Ratio 42.46% 25% F 42% F
Technical Ratios  
Short Ratio 3.37 58% F 46% F
Short Percent 12.75% 12% F 12% F
Beta 2.23 12% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector